| Status | In progress |
| Technology type | Medicine |
| Decision | Selected |
| Process | HST |
| ID number | 3791 |
Provisional Schedule
| Expected publication | 29 March 2023 |
Project Team
| Project lead | Gavin Kenny |
Email enquiries
- If you have any queries please email tateam6@nice.org.uk
Stakeholders
| Companies sponsors | PTC Therapeutics (eladocagene exuparvovec) |
| Others | • Department of Health and Social Care |
| • NHS England | |
| • Welsh Government | |
| Patient carer groups | AADC Trust |
| Professional groups | Royal College of Physicians |
| Comparator companies | NONE |
| General commentators | • All Wales Therapeutics and Toxicology Centre |
| • British National Formulary | |
| • Department of Health, Social Services and Public Safety for Northern Ireland | |
| • Healthcare Improvement Scotland | |
| • Medicines and Healthcare products Regulatory Agency | |
| • Scottish Medicines Consortium | |
| • Welsh Health Specialised Services Committee |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 07 March 2022 | Invitation to participate |
| 18 August 2021 (14:00) | Scoping workshop |
| 01 July 2021 - 29 July 2021 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 15 October 2020 | In progress. topic referral |
For further information on our processes and methods, please see our CHTE processes and methods manual